11.40Open11.40Pre Close0 Volume278 Open Interest250.00Strike Price0.00Turnover39.92%IV-1.84%PremiumJan 17, 2025Expiry Date15.72Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7998Delta0.0168Gamma13.54Leverage Ratio-0.1761Theta-0.0536Rho-10.83Eff Leverage0.1202Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet